Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Net Cash Flow: 2020-2024

Historic Net Cash Flow for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $2.3 million.

  • Tango Therapeutics' Net Cash Flow rose 1105.18% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 183.16%. This contributed to the annual value of $2.3 million for FY2024, which is 60.87% down from last year.
  • According to the latest figures from FY2024, Tango Therapeutics' Net Cash Flow is $2.3 million, which was down 60.87% from $5.8 million recorded in FY2023.
  • In the past 5 years, Tango Therapeutics' Net Cash Flow registered a high of $114.4 million during FY2021, and its lowest value of -$81.1 million during FY2022.
  • Over the past 3 years, Tango Therapeutics' median Net Cash Flow value was $2.3 million (recorded in 2024), while the average stood at -$24.3 million.
  • As far as peak fluctuations go, Tango Therapeutics' Net Cash Flow surged by 1,982.37% in 2021, and later plummeted by 170.88% in 2022.
  • Over the past 5 years, Tango Therapeutics' Net Cash Flow (Yearly) stood at $5.5 million in 2020, then skyrocketed by 1,982.37% to $114.4 million in 2021, then slumped by 170.88% to -$81.1 million in 2022, then spiked by 107.22% to $5.8 million in 2023, then tumbled by 60.87% to $2.3 million in 2024.